Invalidity dossier
US 4956388
3-aryloxy-3-substituted propanamines
Current assignee: Eli Lilly and Co
Added 9/21/2026, 4:01:20 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US4956388A
Title: 3-aryloxy-3-substituted propanamines
Patent number: US4956388A
Application number: US07/462,925
Filing date: 1990-01-12
Publication/grant date: 1990-09-11
Priority date (assumed): 1986-12-22
Inventor(s): David W. Robertson; David T. Wong; Joseph H. Krushinski, Jr.
Original/current assignee: Eli Lilly and Co
Legal status (as listed): Expired – Lifetime; anticipated expiration 2007-09-11
Source: https://patents.google.com/patent/[US4956388](/patent/US4956388)/en
Purpose / plain-language scope (based only on the supplied excerpt):
The patent concerns chemical compounds described as 3-aryloxy-3-substituted propanamines. According to the excerpt's own indexing, the compounds are associated with inhibitory effects on norepinephrine uptake and serotonin uptake and with uses relating to depression (antidepressant/anti-depressive effects), anxiety disorders (anxiety, anxiolytic effects), and obesity (anti-obesity effects). The excerpt also references pharmaceutical compositions and methods, pharmaceutically acceptable salts, carriers, diluents, and excipients, and mentions mammalian subjects (including humans). Claim-oriented terms include alkyl, methyl, ethyl, cycloalkyl, alkoxy, trifluoromethyl, halogen, thienyl/halothienyl, hydrogen, acid, and salts.
What the excerpt does not establish:
The supplied text is a search-page excerpt, not the full patent. It does not provide the complete claims, the full written description, the exact chemical formula(s), the named specific compounds, the detailed synthetic examples, or the precise pharmacological data. The excerpt also does not establish patent validity, enforceability, claim interpretation, ownership history, litigation, or prior-art conclusions; the priority and legal-status dates are expressly stated in the source as assumptions, not legal conclusions.
Generated 10/1/2026, 10:02:38 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 4956388. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.